Commercial Insight: Antidyslipidemics - The competitive cost-conscious antidyslipidemics market presents challenges

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-07-11

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.


Scope

  • Assessment of each of the seven major markets, key drivers for growth and resistors to growth
  • Overview of the main opportunities and threats in each of the seven major markets
  • Forecast analysis including the key events, among them new product launches, major clinical trials and patent expiries.
  • Overview of two case studies (on CETP inhibitors and on the second wave of patent expiries) including worst and best case scenarios.


    • Report Highlights
    Despite over 300m people being eligible for treatment in seven major markets, as well as the recommended treatment goals capturing more patients and promoting more aggressive therapy, there is a lot of under-diagnosis and under-treatment. Cost-saving policies further limit the patient potential for branded agents.

    Lowering of LDL-C treatment goals cannot counteract the impact of cost-saving policies, and does not guarantee a revenue stream for branded agents. This is why there are currently several outcome trials that regard the potential of branded agents (Crestor, Vytorin) in new indications/patient groups, e.g. heart failure and renal disease.

    Branded statins' market share is diminishing. Due to the patent expiries of statins that have taken place in the past five years (especially that of Zocor) and those going to take place in the near future (especially that of Lipitor) the branded statins are losing their market share rapidly.


    Reasons to Purchase

  • Understand key drivers and predict the future performance of key compounds
  • Optimize sales and marketing strategy to counter market threats
  • Develop commercial strategies across the seven major markets

    • Table of Contents

    Other users found this report page using the following search terms: Dyslipidemia Antidyslipidemia Antidyslipidemic obesity cholesterol crestor market generic statin study strategy lipitor 2007 statins case

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.